sponsored
PatientsVille.com Logo

PatientsVille

Bronchiectasis Medical Research Studies

Up-to-date List of Bronchiectasis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Bronchiectasis Medical Research Studies

Rank Status Study
1 Recruiting The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults
Condition: Bronchiectasis
Intervention:
Outcome Measures: The prevalence of respiratory virus infection in adults with Bronchiectasis during a pulmonary exacerbation and when clinically stable.;   The effect of respiratory virus infection on systemic and pulmonary inflammatory markers.;   The effect of respiratory virus on lung function;   The effect of respiratory virus infection on the bacterial load in Bronchiectasis.;   Time to recovery of respective symptom;   The effect of respiratory virus on quality of life in patients with Bronchiectasis;   To investigate if upper respiratory tract symptoms are associated with viral infections.
2 Recruiting ELTGOL and Bronchiectasis. Respiratory Therapy
Conditions: Respiratory; Complications, Therapy;   Bronchiectasis
Interventions: Procedure: Low Expiration Open glottis inferolateral (ELTGOL);   Procedure: Stretching
Outcome Measures: To evaluate the efficacy of ELTGOL in stable state patients with Bronchiectasis compared to placebo;   Side effects, knowledge
3 Recruiting Bacteriology and Inflammation in Bronchiectasis
Condition: Bronchiectasis
Interventions: Drug: Fluroquinolones;   Drug: Beta-lactamase inhibitor
Outcome Measures: Sputum microbiology;   Sputum sol phase inflammatory indices;   24-hour sputum volume;   Spirometry;   Sputum purulence;   Sputum viscosity;   SGRQ total score and the score of each domain;   Time to recovery of respective symptom;   Sputum bacterial clearance rate
4 Not yet recruiting Prevention of OM-85 on Bronchiectasis Exacerbation
Condition: Bronchiectasis With Acute Exacerbation
Intervention: Drug: OM-85
Outcome Measures: Bronchiectasis Exacerbation;   Life quality;   Lung function
5 Recruiting The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis
Condition: Bronchiectasis
Intervention:
Outcome Measures: To evaluate the impact of depression and anxiety symptoms on non-CF Bronchiectasis health outcomes.;   To estimate the prevalence of anxiety and depression symptoms in patients with non-CF Bronchiectasis
6 Unknown  Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis
Conditions: COPD;   Bronchiectasis
Intervention:
Outcome Measure:
7 Recruiting Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis
Condition: Bronchiectasis
Intervention: Drug: Tobramycin
Outcome Measures: Actual dose (dose minus remainder in inhaler after inhalation) of tobramycin;   Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin •Area Under the plasma concentration versus time curve from 0 -12 hours (AUC0-12) of tobramycin;   Maximum plasma concentration (Cmax ) of tobramycin;   Time to maximum plasma concentration (Tmax) of tobramycin;   Absorption rate constant (Ka) of tobramycin;   Terminal elimination half-life (T1/2 el ) of tobramycin;   Clearance following pulmonary administration (CL/F) (F= bioavailability) of tobramycin;   Decrease of FEV1 in percentage measured by spirometry;   Number of Participants with Adverse Events
8 Recruiting Cross-sectional Characterization of Idiopathic Bronchiectasis
Conditions: Idiopathic Bronchiectasis;   Nontuberculous Mycobacterium (NTM) Infection
Intervention:
Outcome Measure:
9 Recruiting Natural History of Bronchiectasis
Conditions: Bronchiectasis;   Cystic Fibrosis;   Autoimmune Disease;   Common Variable Immunodeficiency
Intervention:
Outcome Measure:
10 Unknown  A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
Conditions: Asthma;   Bronchiectasis
Interventions: Drug: DAS181 dry powder, formulation F02;   Drug: Respitose ML006 (DMV-Fonterra)
Outcome Measures: Safety and toxicity profile: Unacceptable Serious Adverse Events;   Assessment of acute tolerability of DAS181 administration in subjects with well-controlled asthma or Bronchiectasis, specifically with regard to airway obstruction (FEV1) and oxyhemoglobin saturation.;   Examine potential effects of DAS181 on underlying lung disease, i.e., as relates to airway hyperreactivity, mucus production, airway inflammation, frequency of acute exacerbations, and health related quality of life measurements.
11 Unknown  Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis
Condition: Bronchiectasis
Interventions: Other: Hypertonic saline;   Other: Isotonic saline
Outcome Measures: 24 hour sputum volume;   Pulmonary Function Testing;   Rheology;   Adherence;   Patient Reported Outcomes RSSQ;   Patient Reported Outcome: Leicester Cough Questionnaire:;   Bronchiectasis Qol Questionnaire
12 Recruiting The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis
Condition: Bronchiectasis
Interventions: Drug: Formoterol-budesonide;   Drug: Theophylline;   Drug: Placebo
Outcome Measures: Quality of Life Assessment with St George's Respiratory Questionnaire(SGRQ) and Leicester Cough Questionnaire(LCQ);   Mean number of exacerbations per patient per 24 weeks;   Changes of sputum characteristics from baseline to 24 weeks;   Changes of 24 hour sputum volume from baseline to 24 weeks;   Changes of forced expiratory volume in 1 second(FEV1) from baseline to 24 weeks;   Changes of mean forced expiratory flow between 25% and 75% of the FVC(FEF25-75)from baseline to 24 weeks;   Changes of forced vital capacity(FVC) from baseline to 24 weeks;   Changes of peak expiratory flow(PEF) from baseline to 24 weeks;   Induced sputum cytology count;   Changes of sputum culture from baseline to 24 weeks;   IL-6;   IL-8;   IL-10;   Tumor necrosis factor(TNF)α;   Activity of histone deacetylase(HDAC);   Activity of histone acetyltransferase(HAT);   8-Isoprostane;   Neutrophilic granulocytes in blood routine examination;   White blood cells in blood routine examination;   Monocytes in blood routine examination;   Eosinophilic granulocytes in blood routine examination;   Number of participants with Adverse events as a measure of safety and tolerability;   Plasma Concentration of Theophylline
13 Unknown  Exercise Capacity in Bronchiectasis Resection
Condition: Bronchiectasis
Intervention:
Outcome Measures: Impact of Pulmonary Resection on Exercise Capacity;   Impact of Pulmonary Resection on Quality of Life.;   Impact of Pulmonary Resection on Lung Function.
14 Recruiting The Effect of Theophylline in the Treatment of Bronchiectasis
Condition: Bronchiectasis
Interventions: Drug: Theophylline;   Drug: Placebo(for Theophylline)
Outcome Measures: Scores of the St.George's Respiratory Questionnaire;   The Number of Exacerbations;   Scores of The Leicester Cough Questionnaire;   24 Hour Sputum Volume;   Activity of histone deacetylase(HDAC);   Activity of histone acetyltransferase(HAT);   Lung function;   Induced sputum culture;   Induced Sputum Cytology Count;   Interleukin-6(IL-6);   C-Reactive Protein;   To evaluate change in patients' Clinical Data;   Number of participants with adverse events;   Plasma Concentration of Theophylline;   IL-8;   IL-10;   Human Tumor Necrosis Factor α(TNF-α);   8-Isoprostane;   Blood routine examination
15 Recruiting A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis
Condition: Bronchiectasis
Interventions: Drug: Tobramycin;   Drug: Saline
Outcome Measures: To evaluate change in density of Pseudomonas aeruginosa in sputum;   To evaluate chang in the amount of sputum;   To evaluate chang in patients' cough severity;   To evaluate change in pulmonary function
16 Not yet recruiting Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection
Condition: Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa
Intervention: Drug: Tobramycin
Outcome Measures: Number of exacerbations as measured by number of systemic courses of antibiotics either PO or IV;   Quality of life and Symptoms Score as measured by SGRQ(Saint George's Respiratory Questionnaire) and CASA-Q-CD (Cough and Sputum Assessment Questionnaire) cough and sputum domains;   Pulmonary function tests (FEV1);   Sputum microbiology: Change in Pseudomona Aeruginosa density in sputum;   Safety and Tolerability of TOBI podhaler
17 Recruiting Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations
Condition: Bronchiectasis
Interventions: Other: Duration;   Drug: Colomycin;   Drug: Meropenem
Outcome Measures: Time to next exacerbation;   Proportion of patients that stopped antibiotics early;   Clinical recovery at days 14 and 21;   Correlation of bacterial load with clinical response;   Antibiotic side effects
18 Recruiting Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis
Condition: Bronchiectasis
Interventions: Other: Pulmonary Rehabilitation;   Dietary Supplement: Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate
Outcome Measures: Change in oxygen uptake at peak exercise (VO2max) in cardiopulmonary exercise test (Before and after Rehabilitation-at 3 and 6 months);   Body composition
19 Recruiting Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin DPI (BAYQ3939);   Drug: Placebo
Outcome Measures: Time to first exacerbation;   Mean number of exacerbations per patient per 48 weeks;   Pathogens present at baseline and eradicated at 48 weeks;   Changes of Saint George's Respiratory Questionnaire score from baseline to 48 weeks;   New pathogens at 48 weeks, not present at baseline;   Changes of Forced expiratory volume in 1 second from baseline to 48 weeks;   Number of participants with Adverse events as a measure of safety and tolerability
20 Recruiting Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin: administered for 28 days on / 28 days off;   Drug: Placebo: administered for 28 days on / 28 days off;   Drug: Ciprofloxacin: administered for 14 days on / 14 days off;   Drug: Placebo: administered for 14 days on / 14 days off
Outcome Measures: Time to first exacerbation;   Mean number of exacerbations per patient per 48 weeks;   Pathogens present at baseline and eradicated at 48 weeks;   Quality of Life: Changes of Saint George's Respiratory;   New pathogens at 48 weeks, not present at baseline;   Changes of Forced Expiratory Volume in 1 second from baseline;   Number of participants with Adverse events as a measure of

These studies may lead to new treatments and are adding insight into Bronchiectasis etiology and treatment.

A major focus of Bronchiectasis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Bronchiectasis